基本信息:
- 专利标题: COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS
- 申请号:PCT/US2020/019695 申请日:2020-02-25
- 公开(公告)号:WO2020176501A1 公开(公告)日:2020-09-03
- 发明人: GAVATHIOTIS, Evripidis , AGIANIAN, Bogos
- 申请人: ALBERT EINSTEIN COLLEGE OF MEDICINE
- 申请人地址: 1300 Morris Park Avenue Bronx, New York 10461 US
- 专利权人: ALBERT EINSTEIN COLLEGE OF MEDICINE
- 当前专利权人: ALBERT EINSTEIN COLLEGE OF MEDICINE
- 当前专利权人地址: 1300 Morris Park Avenue Bronx, New York 10461 US
- 代理机构: MAXWELL, Leslie-Anne
- 优先权: US62/810,056 20190225; US62/810,799 20190226
- 主分类号: C07D211/44
- IPC分类号: C07D211/44 ; C07D241/08 ; C07D265/32 ; C07D265/33 ; C07D295/13 ; C07D295/205 ; C07D401/04 ; C07D403/04 ; C07D487/04 ; A61P35/00 ; A61K31/5377 ; A61K31/506 ; A61K31/495 ; A61K31/5025 ; A61K31/5375 ; A61K31/496 ; A61K31/5395 ; A61K31/501
摘要:
The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables, R A , R B , R C , R D , L 0 , L 1 , L 2 , and L 2 , are defined herein. Compounds and salts of Formula I are useful as inhibitors of RAF kinase dimerization, including dimerization of wild type and mutant BRAF kinases. The disclosure includes pharmaceutical compositions comprising a compound or salt of Formula I. The disclosure also includes methods of treating a cancer susceptible to treatment with an inhibitor of BRAF dimers or BRAF dimerization, comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need of such treatment. These cancers susceptible to treatment with an inhibitor of BRAF dimers or BRAF dimerization include melanoma, thyroid cancer, hairy cell leukemia, ovarian cancer, lung cancer, and colorectal cancer.
IPC结构图谱:
C | 化学;冶金 |
--C07 | 有机化学 |
----C07D | 杂环化合物 |
------C07D211/00 | 杂环化合物,含氢化吡啶环,不与其他环稠合 |
--------C07D211/04 | .只有氢或碳原子直接连在环氮原子上 |
----------C07D211/06 | ..环原子间或环原子与非环原子间无双键 |
------------C07D211/08 | ...有烃基或取代的烃基直接连在环碳原子上 |
--------------C07D211/40 | ....氧原子 |
----------------C07D211/44 | .....连在位置4 |